Ibuprofen B. Braun (Ibuprofen)

Ibuprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for producing prostaglandins. By lowering prostaglandin levels, it reduces inflammation, diminishes pain signals, and helps lower elevated body temperature.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Both ibuprofen and ketorolac are injectable NSAIDs that provide analgesia and antipyresis. Ibuprofen generally has a broader safety margin regarding gastrointestinal irritation, while ketorolac may offer slightly stronger analgesia but carries a higher risk of renal and bleeding complications. Choice depends on the clinical scenario and patient risk profile.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Inspect the solution for particulate matter or discoloration before use.

The medication is given by intravenous infusion. It should be diluted according to the manufacturer’s instructions and administered over the recommended time period, typically 15–30 minutes, under aseptic conditions by qualified healthcare personnel.

Serious adverse events include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions (such as anaphylaxis), and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for these complications, especially if they have pre‑existing risk factors.

Contraindications include patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe uncontrolled hypertension, advanced heart failure, and those with significant renal impairment. It should also be avoided in patients receiving certain anticoagulants without careful risk assessment.